Manju Dawkins, MD, is a board-certified dermatologist and entrepreneur based in the Los Angeles area who founded Thimble Health.

At LEADderm 2026, dermatologist Manju Dawkins, MD, joined a panel called ‘Skin Angels at LEADderm: Building the Next Generation of Dermatology Innovation’ to share her path from clinician to entrepreneur and investor. Dawkins said her own startup is what first pulled her into Skin Angels, a 

-driven angel investing group she now belongs to.

Why Dermatologists Should Have a Seat at the Investment Table, With Manju Dawkins, MD

Dawkins described Skin Angels as an angel group made up of dermatologists and other skin-disease experts who meet regularly to screen hundreds of companies in drug development, aesthetics, AI, and tech. The group holds pitch sessions with the companies it finds most promising, debriefs afterward, and lets each member decide individually whether to invest, and sometimes a member joins a company as an advisor instead.

"I think there's just a lot of opportunity. There's so much new stuff in dermatology, every aspect: drug development, aesthetics, AI in dermatology. There's so much happening, and I think it's really important that we as clinicians play a role in the development. We have to have a voice, and it's important," Dawkins said.

Dawkins said her own startup, Thimble Health, is what led her to Skin Angels in the first place. She described a Prepare patch applied before an injection to numb the skin, and a plant-based Recover patch applied afterward to ease soreness and bruising for up to two days, along with an app in development to address the psychological side of needle fear.

Dawkins pointed to needle phobia as a bigger problem than most clinicians acknowledge, citing an estimate of roughly around 60% of adults experiencing it, a figure in line with published survey research. She said patients receiving the growing wave of injectable biologics and GLP-1 therapies in dermatology deserve tools addressing how the experience feels, not just what the medication does.

Looking beyond her own company, Dawkins said she is excited about dermatology's broader direction: fewer injections over time for some biologics, oral versions of therapies once given only by injection, and more attention to how a treatment actually feels to the person receiving it. She said dermatologists are also opening up to a wider range of approaches beyond pharmaceuticals and surgery, exploring integrative modalities as part of everyday practice.

Editor's Note: This transcript has been edited for grammar and clarity using artificial intelligence tools. Dawkins had no relevant disclosures of note.

Dawkins M, Lio P, et al. Skin Angels at LEADderm: Building the Next Generation of Dermatology Innovation. Session presented at LEADderm. Aug 29-30, 2026.

LEADderm. About LEADderm: the missing curriculum. leadderm.org.

Videos

A dermatologist-turned-entrepreneur on why clinicians belong in dermatology's investment decisions, and what excites her about the field's direction.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

, Lisa Swanson, MD, a board-certified pediatric dermatologist at Ada West Dermatology in Meridian, Idaho, who is on staff at St. Luke's Children's Hospital in Boise, highlighted key takeaways from her session at the LEADderm conference in Newport Beach, CA.

Later in this new segment of her interview, she also described oral Janus-kinase (JAK) inhibitors as being poised to change care for 

, with upadacitinib (Rinvoq) and povorcitinib advancing through late-stage trials for moderate-to-severe disease.

Resilience in Medicine, HS Treatments, and the Oral JAK Pipeline Today

Speaking at LEADderm 2026, Swanson noted her talk, ‘Failure Is the Stepping Stone to Success,’ targets a specific failure she sees often in medicine: chasing an unrealistic standard of perfection. She said the drive to be right every time sets up dermatologists for disappointment more than it protects patients.

"I think all of us in medicine strive to be perfect at all times,” Swanson said. “We strive to get the right diagnosis every time. We try to get the right treatment every time for the patients, and we're just not in a 100% perfect kind of world.

Swanson described the antidote as self-forgiveness, acknowledging effort and treating outcomes as lessons rather than verdicts. She said occasional setbacks build the resilience dermatologists need to keep pursuing the kind of leader, and clinician, they want to become.

Later, she was asked about what she is most anticipating in the 

 pipeline. Povorcitinib, an oral selective JAK1 inhibitor from Incyte, is furthest along in HS: its phase 3 STOP-HS1 trial (NCT05620836) helped enroll about 1,200 patients combined across two studies, and data presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting showed 71% of participants achieved HiSCR50 and 29% reached complete lesion clearance by Week 54. Upadacitinib is advancing through phase 3 testing in HS as well.

Swanson pointed to a pediatric gap in alopecia areata care as well: of the 3 FDA-approved JAK inhibitors, baricitinib (Olumiant) and deuruxolitinib (Leqselvi) are approved only for adults, and ritlecitinib (Litfulo) covers patients 12 and older, leaving no approved option for children under 12. She said earlier treatment is increasingly recognized as important, and closing the gap would let her treat young patients directly rather than relying on off-label use.

Editor's Note: This transcript has been edited for grammar and clarity using artificial intelligence tools. Swanson had no relevant disclosures of note.

LEADderm. About LEADderm: the missing curriculum. 

Incyte's povorcitinib demonstrates lasting efficacy in hidradenitis suppurativa. Managed Healthcare Executive. AAD 2026 coverage. 

https://www.managedhealthcareexecutive.com/view/incyte-s-povorcitinib-demonstrates-lasting-efficacy-in-hidradenitis-suppurativa-aad-2026

FDA-Approved JAK Inhibitors. National Alopecia Areata Foundation. naaf.org.

Lisa Swanson, MD, on embracing failure in medicine and the oral JAK inhibitors advancing for hidradenitis suppurativa and alopecia areata.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

Konstantinos Rizas, MD
Credit: Ludwig Maximilians University

The EPIDAURUS trial was stopped early after potent P2Y12 inhibitors combined with a direct oral anticoagulant (DOAC) increased bleeding without reducing ischemic events in patients with 

 and a recent myocardial infarction (MI), according to results presented at the 

European Society of Cardiology (ESC) Congress 2026

Patients with AF typically receive DOACs to prevent stroke, while patients with a recent MI typically receive dual antiplatelet therapy, often aspirin plus a potent P2Y12 inhibitor, to prevent recurrent ischemic events. Little evidence exists on combining potent P2Y12 inhibitors, prasugrel or ticagrelor, with a DOAC in patients with both conditions, which EPIDAURUS examined.

“In the first trial of its kind, we have answered an important clinical question,” said Konstantinos Rizas, MD, principal investigator and head of the Heart Failure Outpatient Clinic at Ludwig Maximilians University, Munich, Germany. “These findings do not support the routine use of potent P2Y12 inhibitors in combination with direct oral anticoagulants in patients with AF and MI.” 

EPIDAURUS trial design and early termination

EPIDAURUS was a prospective, investigator-initiated, open-label, randomized trial conducted at 37 sites in Germany and Austria, enrolling patients with an indication for oral anticoagulation due to AF who had undergone successful PCI within 5 days for a biomarker-positive MI, with or without ST-segment elevation

. Patients were randomized 1:1 to a DOAC plus prasugrel or ticagrelor for 4 weeks followed by a DOAC plus clopidogrel (experimental group), or a DOAC plus clopidogrel with in-hospital aspirin (control group). Edoxaban, apixaban, and rivaroxaban were the permitted DOACs. The trial planned to enroll 1,474 patients but was stopped after 602 patients (302 experimental, 300 control) following a recommendation from the independent Data and Safety Monitoring Board (DSMB), which cited a low likelihood of demonstrating superiority alongside concordant safety signals including higher numbers of deaths, ischemic strokes, and bleeding events in the experimental group

. Median patient age was 78 years, and 26% were female.

For the primary efficacy endpoint, a hierarchic composite of death, stent thrombosis, MI, ischemic stroke, systemic thromboembolism, and urgent revascularization evaluated 6 weeks after randomization using a win-loss ratio (WLR) analysis, the experimental group showed no significant advantage over control (WLR, 1.19; 95% CI, 0.61-2.32; P = .610 for superiority)

. For the primary safety endpoint, a hierarchic composite of death and Bleeding Academic Research Consortium (BARC) bleeding categories 2 through 3c, the WLR numerically favored the control group without reaching statistical significance for superiority and without meeting the prespecified non-inferiority margin (WLR, 0.66; 95% CI, 0.39-1.11; P = .115 for superiority; P = .713 for non-inferiority).

Bleeding rates and secondary safety findings drove the DSMB decision

In the 6 weeks after randomization, secondary bleeding endpoints ran consistently higher in the experimental group, with BARC grade 3 or greater bleeding occurring more than 3-fold more often than in the control group (hazard ratio, 3.54; 95% CI, 1.15-10.85; P = .028). None of the primary or secondary efficacy endpoints differed significantly between groups at 6 weeks or 6 months across ischemic outcomes including cardiovascular death, MI, and stroke, per the trial’s exploratory secondary analyses.

A landmark analysis using conditional power extrapolated to the originally planned sample size additionally suggested a higher rate of ischemic complications, including ischemic stroke, in the experimental group between weeks 6 and 6 months (hazard ratio, 1.49; 95% CI, 1.08-2.07; 

 = .018), though investigators cautioned this stroke signal did not follow the bleeding-then-ischemia pattern seen in prior studies and requires confirmation in future pooled analyses.

Exploratory subgroup analyses found a nominally significant interaction between sex and ischemic benefit, with no ischemic events among 87 women treated with prasugrel or ticagrelor versus 6 events among 67 women treated with clopidogrel and in-hospital aspirin, alongside a signal for higher bleeding risk among the small number of patients already on a P2Y12 inhibitor at baseline who were escalated to intensified therapy.

Investigators emphasized these subgroup findings were prespecified but exploratory, generated from a prematurely stopped trial with low overall event counts, and should be considered hypothesis-generating rather than confirmatory.

“Many patients who have AF receive direct oral anticoagulants to reduce their risk of stroke. Patients who have recently had a myocardial infarction receive antiplatelet therapy, in particular the combination of aspirin and a potent P2Y12 inhibitor, to reduce their risk of another ischaemic event,” said Rizas.

 “But the optimal regimen for patients suffering from both AF and MI remains unclear.”

The trial authors concluded EPIDAURUS reinforces current guideline preference for clopidogrel and in-hospital aspirin in most patients with AF and acute coronary syndrome requiring oral anticoagulation, and does not support escalation to prasugrel or ticagrelor in this setting given early termination and limited statistical power.

A separate ongoing trial, ADONIS-PCI, is evaluating a related strategy using dabigatran and ticagrelor over a longer treatment duration and may offer complementary evidence.

Rizas KD, Mourouzis K, Rath D, et al. Dual antithrombotic therapy using potent antiplatelet inhibitors in atrial fibrillation and acute coronary syndrome: a randomized controlled trial. Nat Med. Published online August 29, 2026. doi:

European Society of Cardiology. Intensified antiplatelet therapy plus direct oral anticoagulants increased bleeding in patients with atrial fibrillation after a heart attack. Published August 29, 2026. Accessed August 29, 2026.

Articles

EPIDAURUS stopped early after potent P2Y12 inhibitors plus a DOAC raised bleeding without reducing ischemic events in patients with AF and MI.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Arrhythmia

EPIDAURUS Concludes Potent P2Y12 Inhibitors Could Raise Bleeding in AFib, Myocardial Infarction

Øyvind Lie, MD, PhD, MSc
Credit: European Society of Cardiology

A strategy of anticoagulation monotherapy after 

transcatheter aortic valve implantation (TAVI)

 reduced subclinical leaflet thrombosis and was noninferior for bleeding, thromboembolic events, and death compared with antiplatelet monotherapy, according to results of the ACASA-TAVI trial presented at ESC Congress 2026 and published simultaneously in JAMA.

What did the ACASA-TAVI trial find about NOAC monotherapy after TAVI?

NOAC monotherapy reduced subclinical leaflet thrombosis by nearly half compared with aspirin monotherapy (16.2% vs 28.6%) and was noninferior for the composite safety endpoint of bleeding, thromboembolic events, and death.

Was NOAC monotherapy associated with more bleeding than aspirin after TAVI?

No. Overall bleeding rates were low and numerically higher with aspirin, and life-threatening or lethal bleeding events occurred only in the aspirin group.

Does this trial change antithrombotic guidelines after TAVI?

Current guidelines discourage routine anticoagulation without an independent indication; investigators say ACASA-TAVI provides new evidence, which could inform future guideline updates, particularly for younger, lower-risk TAVI patients.

“Thrombus formation on the leaflets of implanted bioprosthetic valves is a potentially preventable cause of early valve dysfunction and has been linked to increased risk of stroke and death,” said Øyvind Lie, MD, PhD, MSc, principal investigator Oslo University Hospital Rikshospitalet, Norway. “However, there is a gap in our knowledge with regards to the optimal antithrombotic therapy after TAVI.”

ACASA-TAVI trial design and primary efficacy findings

ACASA-TAVI was an investigator-initiated, multicenter, prospective, randomized, open-label, blinded-endpoint trial conducted at 3 centers in Norway, enrolling patients aged 65 to 80 years after successful TAVI without an independent indication for anticoagulation or antiplatelet therapy. Of 360 patients randomized 1:1 to 12 months of monotherapy with a factor Xa inhibitor non-vitamin K antagonist oral anticoagulant (NOAC; apixaban, edoxaban, or rivaroxaban) or acetylsalicylic acid (ASA), 336 completed the trial. Mean age was 74.5 years, and 37% were female.

The primary efficacy endpoint, hypoattenuated leaflet thickening (HALT) on blinded core-laboratory cardiac CT at 12 months, occurred in 27 of 167 patients (16.2%) in the NOAC group versus 48 of 168 patients (28.6%) in the ASA group (risk ratio, 0.55; 95% CI, 0.37-0.82; 

 = .004). More severe HALT (grade 2 or higher) was substantially more prevalent in the ASA group, while grade 1 HALT rates were similar between groups.

Safety noninferiority and mortality signal with NOAC monotherapy

The co-primary safety endpoint, a composite of Valve Academic Research Consortium 3 bleeding events, thromboembolic events, and all-cause death at 12 months, occurred in 13 patients (7.5%) in the NOAC group versus 19 patients (10.6%) in the ASA group, meeting the prespecified noninferiority margin (risk difference, -3.3%; 95% CI, -9.5% to 2.8%; 

 for noninferiority < .001). Two patients in the NOAC group died during the trial compared with 10 in the ASA group (risk difference, -4.4%; 95% CI, -8.9% to -0.6%), a finding investigators characterized as exploratory given the trial was not powered for individual safety components. Life-threatening (VARC-3 type 3) and lethal (type 4) bleeding events occurred only in the ASA group, and overall bleeding rates were low and numerically higher with ASA.

“Clinicians may perceive the bleeding risk of anticoagulants to be higher than that of antiplatelet agents, but we found in this study that life-threatening and lethal bleeding occurred only in patients in the ASA group,” said Lie.

Investigators noted the recommendation against routine anticoagulation after TAVI has rested on trials evaluating combinations of anticoagulants and antiplatelet agents rather than head-to-head monotherapy comparisons, and positioned ACASA-TAVI as addressing this evidence gap directly for younger, lower-risk TAVI populations where valve durability is a key long-term concern.

The trial investigators cautioned findings may not extrapolate to patients older than 80 years, and noted the open-label design could have influenced medication adherence and adverse-event reporting.

“We were able to show substantial reductions in signs of subclinical leaflet thrombosis with NOAC monotherapy, without compromising safety,” said Lie. “Results from the ACASA-TAVI trial may establish a new antithrombotic treatment paradigm after TAVI and could be used to inform future guidelines.”

Dodgson CS, Herstad J, Kløve SF, et al. Anticoagulation monotherapy vs antiplatelet monotherapy after transcatheter aortic valve implant: the ACASA-TAVI randomized clinical trial. JAMA. Published online August 30, 2026. doi:

European Society of Cardiology. What is the best approach to reduce clots on the new heart valve after TAVI? Published August 30, 2026. Accessed August 30, 2026.

ACASA-TAVI found NOAC monotherapy cut subclinical leaflet thrombosis nearly in half versus aspirin after TAVI, meeting safety noninferiority.

ACASA-TAVI: NOAC Monotherapy Cuts Leaflet Thrombosis

Ashkan Shoamanesh, MD, is an associate professor of medicine and the Marta and Owen Boris Chair in Stroke Research and Care at McMaster University.

, found no net benefit from edoxaban among unselected patients with atrial fibrillation (AF) and a prior intracranial hemorrhage (ICH), with excess bleeding offsetting reductions in ischemic events.¹

Ashkan Shoamanesh, MD, of McMaster University, principal investigator of the trial, discussed with 

 how clinicians might individualize care in this population going forward.

Not All Intracranial Hemorrhage Is the Same, With Ashkan Shoamanesh, MD

Not All Intracranial Hemorrhage is the Same

Asked whether prior ICH is too broad a category for clinical decision-making, and whether hemorrhage location or underlying cerebral small vessel disease should factor in instead, Shoamanesh agreed.

"Not all ICH are the same. The natural history and underlying disease that drives subdural hemorrhages is very different than the natural history and underlying disease that drives lobar ICH or convexity bleeds," he said, noting non-lobar ICH is predominantly driven by hypertensive arteriopathy and arteriosclerosis, distinct from the cerebral amyloid angiopathy typically underlying lobar and convexity hemorrhage.

Shoamanesh said a trial powered for a single ICH subtype in isolation would be nearly impossible to conduct. He noted the global initiative behind ENRICH-AF, activating 240 sites and enrolling for years to accumulate its combined study population, illustrates just how difficult recruitment is in this population, with an average enrollment rate of roughly 2 patients per center per year across the broader, lumped strategy the trial ultimately used.²

Balancing Thromboembolic and Bleeding Risk

The trial enrolled patients with high-risk AF, defined by a CHA2DS2-VASc score of ≥ 2, though prior ICH itself did not contribute points toward the score; only an actual history of ischemic stroke or transient ischemic attack did.² The average CHA2DS2-VASc score was 4, and the annualized ischemic stroke rate was approximately 5.5%, reflecting an already high-risk population for ischemic stroke.² Even at higher CHA2DS2-VASc levels, Shoamanesh said stratified analyses showed no clear anticoagulation benefit.

Shoamanesh said stroke risk is unlikely to be the key differentiator for treatment decisions. "I really think that the key discrimination here is on the safety side, not on the ischemic stroke side, and... it's the lower-risk bleeding groups that may have benefit... or a lower dose of an anticoagulant that can have greater safety, but still have some efficacy," he said, adding that factor XI inhibitors, currently being studied for AF more broadly, represent a compelling potential option given their theoretically safer bleeding profile.

On left atrial appendage occlusion (LAAO) as an alternative strategy, Shoamanesh said he now refers patients with lobar or convexity ICH for consideration, prescribing edoxaban 15 mg for those who are not candidates or decline the procedure but have sufficient ischemic stroke risk. He cautioned against assuming LAAO is the default answer, however. "Just assuming that LAAO is the answer is the wrong approach. I think we need an RCT showing that LAAO is the preferred approach in this population," Shoamanesh said, pointing to the CLOSURE-AF trial, testing LAAO in the frailest population studied with the device to date, which was recently stopped for futility. "In the interim, we do our best clinically through guesswork."

On what the ongoing ASPIRE trial, a double-blind comparison of apixaban with aspirin, might add beyond ENRICH-AF, Shoamanesh said he expects dosing, rather than drug choice, to be the key differentiator. He cited prior excess bleeding signals with apixaban in the smaller APACHE-AF trial and the larger PRESTIGE-AF trial as evidence the different DOACs are unlikely to behave differently from edoxaban in this population.³ He described ENRICH-AF's broader lesson as a caution against assuming findings from general AF populations generalize to frail, high-risk subgroups such as ICH survivors, a caution he said extends to LAAO as well as anticoagulation.

Editors’ note: Shoamanesh reports relevant disclosures with AstraZeneca, Bayer AG, Daiichi Sankyo, and others.

European Society of Cardiology. Safer stroke prevention strategies are needed for patients with atrial fibrillation after intracranial haemorrhage. Published August 29, 2026. Accessed August 30, 2026.

Shoamanesh A, et al. ENRICH-AF: edoxaban in intracranial hemorrhage survivors with atrial fibrillation. Presented at: ESC Congress 2026; August 29, 2026; Munich, Germany.

Veltkamp R, Korompoki E, Harvey KH, et al. Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2025;405(10482):927-936. doi:10.1016/S0140-6736(25)00333-2

Ashkan Shoamanesh, MD, discusses individualizing stroke prevention after ENRICH-AF, from LAAO to factor XI inhibitors to the ASPIRE trial.

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Beyond Edoxaban: Rethinking Stroke Prevention, With Ashkan Shoamanesh, MD

Abigail Brooks is a strategic content lead overseeing 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

SHASTA-3 and SHASTA-4 found plozasiran cut triglycerides by roughly 80% and acute pancreatitis events by 78% in severe hypertriglyceridemia.

Dyslipidemia

Plozasiran Cuts Triglycerides By 80% in SHASTA-3/4 Trials

Ashkan Shoamanesh, MD, explains ENRICH-AF's mixed stroke and bleeding results, and a dosing signal that may point to a safer approach.

ENRICH-AF: A Dosing Clue Emerges After Edoxaban's Miss, With Ashkan Shoamanesh, MD

Ashish Sarraju, MD, is a cardiologist in the Heart, Vascular & Thoracic Institute at Cleveland Clinic.

Ashish Sarraju, MD, discusses phase 1 data showing a single dose of Kylo-11 durably reduced lipoprotein(a) through 48 weeks.

Strategic Alliance Partnership

Kylo-11 Shows Durable Lp(a) Reduction at 48 Weeks, With Ashish Sarraju, MD

Luke Laffin, MD, is the co-director of the Center for Blood Pressure Disorders, medical director of cardiac rehabilitation, and associate professor of medicine at Cleveland Clinic.

Luke Laffin, MD, discusses 1-year data showing CTX310 produced durable reductions in ANGPTL3, LDL cholesterol, and triglycerides.

Gene Editing for Lipids: 1-Year CTX310 Data, With Luke Laffin, MD

CMR GUIDE found ICD implantation did not significantly reduce sudden cardiac death or dangerous arrhythmia versus a loop recorder in LVEF 36-50%.

ICD Fails to Reduce SCD/HSVA in CMR GUIDE Trial

Ronald Witteles, MD, is a professor of cardiovascular medicine at Stanford University and co-director of the Stanford Amyloid Center and the Stanford Multidisciplinary Sarcoidosis Program

Ronald Witteles, MD, explains why CARDIO-TTRansform's miss doesn't undermine TTR silencers as a class for treating ATTR-CM.

The Future of Gene Silencers for ATTR-CM After CARDIO-TTRansform, With Ronald Witteles, MD

Phase 2b LUMINARA results showed the oral relaxin agonist AZD5462 improved echocardiographic measures of cardiac function in patients with chronic heart failure.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

AZD5462 Improves Cardiac Function in Phase 2b LUMINARA Trial

The Met-HeFT trial and a companion meta-analysis found metformin did not significantly improve cardiovascular outcomes in patients with HFrEF.

Metformin Shows No Cardiovascular Benefit in HFrEF: Met-HeFT Trial Findings

Lisa Swanson, MD, on treating professional failure as a source of direction and resilience in her LEADderm 2026 talk.

How Failure Is the Stepping Stone to Success, With Lisa Swanson, MD

Adam Friedman, MD, traces dermatology's yes-first culture to residency competition, previewing an unrehearsed LEADderm 2026 negotiation exercise.

Latest News

Why Dermatologists Should Have a Seat at the Investment Table, With Manju Dawkins, MD

Resilience in Medicine, HS Treatments, and the Oral JAK Pipeline Today

EPIDAURUS Concludes Potent P2Y12 Inhibitors Could Raise Bleeding in AFib, Myocardial Infarction

ACASA-TAVI: NOAC Monotherapy Cuts Leaflet Thrombosis

Beyond Edoxaban: Rethinking Stroke Prevention, With Ashkan Shoamanesh, MD